Gunter U Hoglinger
Overview
Explore the profile of Gunter U Hoglinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
252
Citations
10136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scheifele M, Gnorich J, Schroder E, Kunte S, Ells Z, Hagen J, et al.
Eur J Nucl Med Mol Imaging
. 2025 Mar;
PMID: 40064709
Purpose: Due to new advances in molecular and imaging biomarkers, a biological classification of Parkinson's disease (PD) called SyNeurGe (Hoglinger et al. Lancet Neurol 2024;23:191-204) has been proposed for research...
2.
Wang H, Chang T, Dombroski B, Cheng P, Si Y, Tucci A, et al.
Mov Disord
. 2025 Mar;
PMID: 40055946
Background: The 17q21.31 region with various structural forms characterized by the H1/H2 haplotypes and three large copy number variations (CNVs) represents the strongest risk locus in progressive supranuclear palsy (PSP)....
3.
Reese R, Koeglsperger T, Schrader C, Tonges L, Deuschl G, Kuhn A, et al.
J Neurol
. 2025 Feb;
272(3):219.
PMID: 39985674
Background: Parkinson's disease (PD) is characterized by hypokinetic motor symptoms, tremor, and various non-motor symptoms with frequent fluctuations of symptoms in advanced disease stages. Invasive therapies, such as deep brain...
4.
Bernhardt A, Longen S, Trossbach S, Rossi M, Weckbecker D, Schmidt F, et al.
Acta Neuropathol
. 2025 Feb;
149(1):20.
PMID: 39976789
Misfolded α-synuclein (αSyn) is the hallmark of α-synucleinopathies such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). While seed amplification assays (SAA) have demonstrated...
5.
Hoglinger G, Lang A
J Parkinsons Dis
. 2025 Feb;
:1877718X241298194.
PMID: 39973492
While significant progress has been made in treating Parkinson's disease (PD) symptoms, disease-modifying therapies (DMTs) have consistently failed. To address the underlying molecular mechanisms of PD, two biology-based criteria have...
6.
Gesierich B, Sander L, Pirpamer L, Meier D, Ruberte E, Amann M, et al.
Hum Brain Mapp
. 2025 Feb;
46(3):e70141.
PMID: 39936343
Disorders of the central nervous system, including neurodegenerative diseases, frequently affect the brainstem and can present with focal atrophy. This study aimed to (1) optimize deep learning-based brainstem segmentation for...
7.
Porsche S, Klietz M, Greten S, Piot I, Jensen I, Wegner F, et al.
Mov Disord Clin Pract
. 2025 Jan;
PMID: 39868903
Background: Patients with Progressive Supranuclear Palsy (PSP) suffer from several neuropsychological impairments. These mainly affect the frontal lobe and subcortical brain structures. However, a scale for the assessment of cognitive...
8.
Roemer-Cassiano S, Wagner F, Evangelista L, Rauchmann B, Dehsarvi A, Steward A, et al.
Sci Transl Med
. 2025 Jan;
17(782):eadp2564.
PMID: 39841807
In Alzheimer's disease (AD), amyloid-β (Aβ) triggers the aggregation and spreading of tau pathology, which drives neurodegeneration and cognitive decline. However, the pathophysiological link between Aβ and tau remains unclear,...
9.
Hornung S, Vogl D, Naltsas D, Volta B, Ballmann M, Marcon B, et al.
Angew Chem Int Ed Engl
. 2025 Jan;
:e202422834.
PMID: 39822034
Amyloid self-assembly of α-synuclein (αSyn) is linked to the pathogenesis of Parkinson's disease (PD). Type 2 diabetes (T2D) has recently emerged as a risk factor for PD. Cross-interactions between their...
10.
Quattrone A, Franzmeier N, Levin J, Petzold G, Spottke A, Brosseron F, et al.
Mov Disord
. 2025 Jan;
PMID: 39797511
Background: The recent Movement Disorders Society (MDS)-progressive supranuclear palsy (PSP) diagnostic criteria conceptualized three clinical diagnostic certainty levels: "suggestive of PSP" for sensitive early diagnosis based on subtle clinical signs,...